Immunotherapy plus radiation before surgery for liver cancer with portal vein tumor clot
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests combining an immunotherapy drug (sintilimab) with focused radiation (SBRT) before surgery for liver cancer that has spread into a branch of the portal vein. The goal is to see if this combination can shrink the tumor and make surgery more successful.
Summary written for real people, not researchers, by Clin2.
Who can take part
- At least 18 years old
- Diagnosed with liver cancer (hepatocellular carcinoma) that has spread into a branch of the main vein carrying blood to the liver, but the tumor can still be surgically removed after consultation with a team of specialists
- No prior cancer treatment (like surgery, radiation, chemotherapy, or targeted therapy) for this liver cancer
- Good overall health, able to perform daily activities with little or no help
- Adequate liver and kidney function, as shown by blood tests
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (ipilimumab and nivolumab) plus targeted radiation (SBRT) for people with liver cancer that is advanced but has not spread outside the liver. The goal is to see if this approach can shrink tumors and make them easier to remove with surgery.
This study tests whether adding two immunotherapy drugs (durvalumab and tremelimumab) plus radiation before surgery works better than radiation alone before surgery for people with resectable liver cancer. It's for those with a single tumor (or a few small nearby spots) that hasn't spread.
This trial tests whether combining radiation (IMRT) with two drugs—camrelizumab (an immunotherapy) and apatinib (a targeted therapy)—before surgery can help people with liver cancer that has spread to the main blood vessel of the liver (portal vein). The goal is to shrink the tumor and improve surgical outcomes.
This trial tests whether combining the immunotherapy drug sintilimab with targeted radiation therapy before surgery can improve outcomes for patients with liver cancer that can be surgically removed. It aims to shrink the tumor and reduce the chance of recurrence.
This trial tests adding radiation (SBRT) to a combination of immunotherapy drugs (atezolizumab and bevacizumab) for people with liver cancer that has spread into the main portal vein. It aims to see if this approach can shrink tumors and improve outcomes.
This trial tests a combination of targeted radiation (SBRT) and immunotherapy for people with small liver cancers that have come back or are still present after prior treatment. It aims to see if this approach can better control the cancer without using heavy chemotherapy.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.